Annals of Surgical Treatment and Research

The Korean Surgical Society (대한외과학회)
권호 표지
DOI QR코드

DOI QR Code

Development of second primary cancer in Korean breast cancer survivors

  • Jung, Hong Kyu (Department of Surgery, Seran General Hospital) ;
  • Park, Suyeon (Department of Biostatistics, Soonchunhyang University Seoul Hospital) ;
  • Kim, Nam Won (Department of Surgery, Soonchunhyang University Seoul Hospital) ;
  • Lee, Jong Eun (Department of Surgery, Soonchunhyang University Cheonan Hospital) ;
  • Kim, Zisun (Department of Surgery, Soonchunhyang University Bucheon Hospital) ;
  • Han, Sun Wook (Department of Surgery, Soonchunhyang University Cheonan Hospital) ;
  • Hur, Sung Mo (Department of Surgery, Soonchunhyang University Bucheon Hospital) ;
  • Kim, Sung Young (Department of Surgery, Soonchunhyang University Cheonan Hospital) ;
  • Lim, Cheol Wan (Department of Surgery, Soonchunhyang University Bucheon Hospital) ;
  • Lee, Min Hyuk (Department of Surgery, Soonchunhyang University Seoul Hospital) ;
  • Lee, Jihyoun (Department of Surgery, Soonchunhyang University Seoul Hospital)
  • Received : 2017.04.05
  • Accepted : 2017.05.23
  • Published : 2017.12.01
⟨ Previous Next ⟩

Abstract

Purpose: Breast cancer survivors have slightly increased the risk of second primary cancers. Breast, colon, uterine, and ovarian cancers are common secondary cancers in breast cancer survivors. In this study, we assessed the development of second primary cancers of breast cancer survivors in Korea. Methods: Medical records of patients with breast cancer in 3 tertiary medical institutions were reviewed retrospectively. We evaluated secondary malignancy diagnosed at least 2 months after the breast cancer diagnosis. Based on the International Classification of Disease-9 codes of malignancies, secondary primary breast cancer records were evaluated with person-year adjustment. The standardized incidence ratio (SIR) was assessed using national cancer incidence. Results: A total of 3,444 treatment records were included from 3 medical centers. The cumulative incidence of overall second primary cancers was 2.8% (n = 93). The SIR was significantly higher in all sites (1.56; 95% confidence interval [CI], 1.26-1.91), endometrial cancer (5.65; 95% CI, 2.06-12.31), biliary tract cancer (3.96; 95% CI, 1.19-8.60), and thyroid cancer (2.29; 95% CI, 1.67-3.08). Conclusion: The incidence of cancer was higher in breast cancer survivors compared to general population. Surveillance of secondary cancer in this group should be recommended individually considering the benefit related to the prognosis of primary breast cancer.

Keywords

Acknowledgement

Supported by : Korea Breast Cancer Foundation, Soonchunhyang University

References

  1. Oh CM, Won YJ, Jung KW, Kong HJ, Cho H, Lee JK, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat 2016; 48:43650.
  2. National Cancer Center. Annual report of cancer statistics in Korea in 2012. Goyang (Korea): National Cancer Center; 2014.
  3. Curtis RE, Freedman DM, Ron E, Ries LA, Hacker DG, Edwards BK, editors. New malig nancies among cancer survivors: SEER Cancer Registries, 19732000. National Cancer Institute. NIH Publ. No. 055302. Bethesda (MD): National Cancer Institute; 2006.
  4. Hulka BS, Brinton LA. Hormones and breast and endometrial cancers: preven tive strategies and future research. Environ Health Perspect 1995;103 Suppl 8: 1859.
  5. La Vecchia C, Brinton LA, McTiernan A. Cancer risk in menopausal women. Best Pract Res Clin Obstet Gynaecol 2002;16: 293307.
  6. Brinton LA, Moghissi KS, Scoccia B, Westhoff CL, Lamb EJ. Ovulation induction and cancer risk. Fertil Steril 2005;83:26174.
  7. DruesnePecollo N, Touvier M, Barrandon E, Chan DS, Norat T, Zelek L, et al. Excess body weight and second primary cancer risk after breast cancer: a systematic review and metaanalysis of prospective studies. Breast Cancer Res Treat 2012;135:64754.
  8. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Metaanalysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:93747.
  9. Yu GP, Schantz SP, Neugut AI, Zhang ZF. Incidences and trends of second can cers in female breast cancer patients: a fixed inception cohortbased analysis (United States). Cancer Causes Control 2006;17: 41120.
  10. Andersson M, Jensen MB, Engholm G, Henrik Storm H. Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 19772001. Acta Oncol 2008;47:75564.
  11. Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, et al. Risk of second cancer among women with breast cancer. Int J Cancer 2006;118:228592.
  12. Volk N, PompeKirn V. Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 1997;8:76470.
  13. Tanaka H, Tsukuma H, Koyama H, Kinoshita Y, Kinoshita N, Oshima A. Second primary cancers following breast cancer in the Japanese female population. Jpn J Cancer Res 2001;92:18.
  14. Kim JY, Song HS. Metachronous double primary cancer after treatment of breast cancer. Cancer Res Treat 2015;47:6471.
  15. Raymond JS, Hogue CJ. Multiple pri mary tumours in women following breast cancer, 19732000. Br J Cancer 2006;94:174550.
  16. Kamigaki Y, Kawakami K. Risk of second can cer after initial treatment of breast can cer: an Osaka Cancer Registry Database study. Oncol Lett 2011;2:96373.
  17. Joseph KR, Edirimanne S, Eslick GD. The association between breast cancer and thyroid cancer: a metaanalysis. Breast Cancer Res Treat 2015;152:17381.
  18. Morton LM, Dores GM, Tucker MA, Kim CJ, Onel K, Gilbert ES, et al. Evolving risk of therapyrelated acute myeloid leukemia following cancer chemotherapy among adults in the United States, 19752008. Blood 2013;121:29963004.
  19. PetersEngl C, Frank W, Danmayr E, Friedl HP, Leodolter S, Medl M. Association between endometrial cancer and tamoxifen treatment of breast cancer. Breast Cancer Res Treat 1999;54:25560.
  20. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifentreated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B14. J Natl Cancer Inst 1994;86:52737.
  21. Chlebowski RT, Schottinger JE, Shi J, Chung J, Haque R. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer 2015;121: 214755.
  22. Brown LM, Chen BE, Pfeiffer RM, Schairer C, Hall P, Storm H, et al. Risk of second nonhematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat 2007;106:43951.
  23. MolinaMontes E, Requena M, SsnchezCantalejo E, Fernandez MF, ArroyoMorales M, Espin J, et al. Risk of second can cers cancer after a first primary breast can cer: a systematic review and metaanalysis. Gynecol Oncol 2015;136:15871.
  24. Wilbur J. Surveillance of the adult cancer survivor. Am Fam Physician 2015;91:2936.

Cited by

  1. Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a hist vol.473, pp.2, 2017, https://doi.org/10.1007/s00428-018-2390-5
  2. Nationwide Analysis of Treatment Patterns for Korean Breast Cancer Survivors Using National Health Insurance Service Data vol.33, pp.44, 2018, https://doi.org/10.3346/jkms.2018.33.e276
  3. Gastric Complications after Adjuvant Radiotherapy for Breast Cancer vol.22, pp.3, 2017, https://doi.org/10.4048/jbc.2019.22.e42
  4. A Linkage Between Thyroid and Breast Cancer: A Common Etiology? vol.28, pp.4, 2017, https://doi.org/10.1158/1055-9965.epi-18-0877
  5. Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study vol.24, pp.8, 2017, https://doi.org/10.1007/s10147-019-01430-0
  6. Risk of multiple primary tumors in breast cancer survivors vol.559, pp.None, 2020, https://doi.org/10.1088/1755-1315/559/1/012028
  7. Risk factors and prediction of second primary cancer in primary female non-metastatic breast cancer survivors vol.12, pp.19, 2020, https://doi.org/10.18632/aging.103939
  8. Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study vol.11, pp.12, 2017, https://doi.org/10.1038/s41408-021-00595-0